Xilonix Promising for Patients With Advanced or Refractory Colorectal Cancer

Share this content:
Novel therapy is promising for patients with advanced colorectal cancer.
Novel therapy is promising for patients with advanced colorectal cancer.

The novel anti-interleukin 1-alpha antibody, xilonix, is the first immunotherapy to target interleukin-1 alpha, and promises to be an effective treatment for patients with metastatic colorectal cancer, according to a study presented at the 18th annual World Congress of Gastrointestinal Cancer in Barcelona, Spain.1

Interleukin-1 alpha promotes angiogenesis within tumors, causes the body to burn muscle, and can lead to fatigue, anxiety, and anorexia for patients with advanced cancer. Researchers enrolled 309 patients to this phase 3, 2:1 randomized study; patients were assigned to receive either xilonix or placebo; each patient had metastatic colorectal cancer, had failed standard chemotherapy treatment, and displayed a high number of symptoms, including systemic inflammation.

Patients who received xilonix had a 76% increased clinical response rate, and had an average overall survival of 7.3 months longer, than patients who received placebo (11.5 versus 4.2 months, respectively, P = .0045). Improvements were recorded for almost all other health-related measures for patients who received xilonix, including reduced systemic inflammation. These patients were also 25% less likely to experience adverse events.

RELATED: Genetic Picture of Colorectal Cancer Clarified

The researchers concluded that this novel therapy is promising for patients with advanced colorectal cancer, and further that an examination of a patient's “health status,” understood as observable symptoms relating to disease, ought to be considered a measure of treatment efficacy for patients in this disease group.


1. Hickish T, Thierry A, Lucjan W, et al. A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. Paper presented at: European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer; July 2016; Barcelona, Spain.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs